Alport syndrome

Nov 06, 2018

Regulus Announces Successful Restructuring of Sanofi Collaboration

Oct 30, 2018

Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-b-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS)

Oct 25, 2018

Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

Oct 24, 2018

Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-b-Cyclodextrin (2HPbCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)

Oct 16, 2018

Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-b-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)

Aug 03, 2018

Kidney Patients with Alport Syndrome are Center of FDA Patient-Focused Meeting

Jun 01, 2018

Alport Syndrome Pipeline Analysis 2018: 5 Drugs Currently in Different Phases of Development

Apr 16, 2018

Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease